Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
CC transcript
Quarterly results
Appointed director
|
|
ACURA PHARMACEUTICALS, INC (ACUR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/16/2023 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets Interacti... |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia... |
| 06/30/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 06/30/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS December 31, December 31, 2021 2020 Assets – current $ 372 $ 1,179 Property, plant and equipment, net 438 484 Other assets 50 73 Total assets $ 860 $ 1,736 Other liabilities - current $ 515 $ 680 Loan under CARES Act - current - 164 Accrued interest to related party – current - 678 Convertible debt to related party – current - 6,000 Loan under CARES Act – non current - 105 Promissory note to related party – non current 150 - Other liabilities – non current 17 - Stockholders' equity 178 Total liabilities and stockholders' equity $ 860 $ 1,736 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS" |
|
| 05/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia... |
| 03/20/2023 |
8-K
| Quarterly results |
| 02/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia... |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/02/2023 |
8-K
| Other Events Interactive Data |
| 01/20/2023 |
8-K
| Quarterly results |
| 12/27/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/17/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/26/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/26/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/28/2022 |
8-K
| Quarterly results |
| 07/19/2022 |
8-K
| Quarterly results |
| 07/14/2022 |
8-K
| Quarterly results |
| 07/11/2022 |
8-K
| Quarterly results |
| 06/13/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
8-K
| Quarterly results |
| 05/19/2022 |
8-K
| Quarterly results |
| 05/02/2022 |
8-K
| Quarterly results |
| 04/04/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/01/2022 |
8-K
| Quarterly results |
| 02/15/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/01/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 01/04/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/28/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/17/2021 |
8-K
| Quarterly results|
Docs:
|
"Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results Palatine, IL – - Acura Pharmaceuticals, Inc. , an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021. The Company reported revenues of $270 thousand, an operating loss of $531 thousand and a net loss of $262 thousand or $0.00 per diluted share for the third quarter 2021 compared to revenues of $410 thousand, an operating loss of $565 thousand and a net loss of $678 thousand or $0.02 per diluted share for the same period in 2020. For the nine months ended September 30, 2021, the Company reported revenues of $1.5 million, a..." |
|
| 08/17/2021 |
8-K
| Quarterly results |
|
|
|